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Abstract: This study investigated the protective effects of a lipid extract from hard-shelled mussel
(HMLE) on intestinal integrity and the underlying mechanisms after a lipopolysaccharide (LPS)
challenge in mice by using a 3 × 2 factorial design. Mice received olive oil, fish oil, and HMLE
(n = 12 per group) by using gastric gavage for six weeks, respectively. Then half the mice in each
group was injected intraperitoneally with LPS and the other half with phosphate buffered saline.
Four hours after injection, mice were sacrificed and samples were collected. n-3 PUFAs were
significantly enriched in erythrocytes following fish oil and HMLE supplementation. Both fish
oil and HMLE improved intestinal morphology by restoring the ileac villus height and barrier
function, which is indicated by decreased colonic myeloperoxidase activity and increased diamine
oxidase activity as well as enhanced mRNA expression of intestinal tight junction proteins known
as occludin and claudin-1 when compared with olive oil. In addition, both fish oil and HMLE
increased colon production and the expression of anti-inflammatory cytokine, IL-10, while they
inhibited the abnormal production and expression of pro-inflammatory cytokines including TNF-α,
IL-1β, and IL-6 relative to the olive oil. Lastly, in comparison with olive oil, both fish oil and HMLE
downregulated the TLR-4 signaling pathway by reducing the expression of two key molecules in this
pathway, which are called TLR-4 and MyD88. These results suggest that HMLE had a protective effect
on intestinal integrity after the LPS challenge, which was equivalent to that of fish oil. This effect
might be associated with the regulation of inflammatory mediators and the inhibition of the TLR-4
signaling pathway.
Keywords: hard-shelled mussel; Mytilus coruscus; intestinal integrity; lipopolysaccharide; TLR-4
signaling pathway
1. Introduction
Intestinal integrity is very important since it constitutes an essential barrier to protect against
the diffusion of pathogens, toxins, and allergens from the external environment [1,2]. However,
many factors such as infection and inflammation can induce intestinal injury especially disruption
of the intestinal barrier [3]. A dysfunctional intestinal barrier is associated with the pathophysiology
of various diseases and disorders such as inflammatory bowel disease, irritable bowel syndrome,
and celiac disease [1]. It has been widely accepted that over-release of pro-inflammatory cytokines
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play a crucial role in intestinal barrier disturbance through different mechanisms including induction
of gross lesions, reduction in tight junction strands, upregulation of epithelial apoptosis, and arrested
epithelial restitution [4,5]. Therefore, anti-inflammatory treatment aimed to inhibit the production of
intestinal pro-inflammatory cytokines may have beneficial effects in alleviating intestinal injury.
The hard-shelled mussel (Mytilus coruscus) is the main mussel species commonly cultivated
in coastal areas of China and is the most representative mollusk in the Chinese bivalve market [6].
Our previous study examining its nutrient composition showed that a hard-shelled mussel is rich in n-3
polyunsaturated fatty acids (PUFA) ranging from 34% to 37% of total fatty acids [7]. Eicosapentaenoic
acid (EPA, 11–15% of total fatty acids) and docosahexaenoic acid (DHA, 12–18%) are the most
abundant n-3 PUFA. Long chain n-3 PUFA such as EPA and DHA are generally believed to have
anti-inflammatory effects [8–10] and have been used as immune modulators [11,12]. Therefore,
EPA-rich and DHA-rich hard shelled mussel could be used as part of an anti-inflammatory treatment.
In recent years, both animal and human studies have demonstrated that the lipid extract from
hard-shelled mussels (hard-shelled mussel lipid extract, HMLE) exert strong anti-inflammatory effects
on arthritis and inflammatory bowel disease [6,13–15]. Further examination showed that HMLE could
downregulate pro-inflammatory cytokines including the tumor necrosis factor (TNF)-α, interleukin
(IL)-1β and IL-6, and upregulated anti-inflammatory cytokines including IL-4 and IL-10, which
indicates that the strong activity may be ascribed to the regulation of balance between pro-inflammatory
and anti-inflammatory cytokines [15]. However, there is no report on the anti-inflammatory effects of
HMLE on intestinal injury and the underlying molecular mechanism(s).
In this study, we aimed to investigate the potential protective effects of HMLE on intestinal
integrity after a lipopolysaccharide (LPS) challenge in mice. We performed intestinal morphology
examination and measured the colon tissue concentration of myeloperoxidase (MPO), which is an
inflammation marker whose concentration increases and undergoes inflammation, and diamine
oxidase (DAO), which is a mucosal injury marker that decreases when mucosal cells are injured,
and cytokines such as IL-1β, IL-6, IL-10, and TNF-α. In addition, we determined the mRNA expression
of tight junction proteins including occludin and claudin-1, which are major determinants of an
intestinal barrier function [16]. In order to explore the intracellular signaling mechanism underlying
the potential effect of HMLE, we also measured the mRNA expression of cytokines and key molecules
in a toll-like receptor (TLR)-4 signaling pathway, which is a pathway related to the intestinal mucosa
barrier function [17]. These molecules include TLR-4, myeloid differentitation factor 88 (MyD88), IL-1
receptor-associated kinase (IRAK)-4, and TNF receptor-associated factor (TRAF)-6.
2. Materials and Methods
2.1. Chemicals and Reagents
Olive oil was purchased from a local supermarket in Hangzhou. Fish oil was purchased from
Neptunus Bioengineering Co., Ltd., (Hangzhou, China). LPS was obtained from Sigma-Aldrich
(St. Louis, MO, USA). Commercial kits for determining myeloperoxidase (MPO) and diamine
oxidase (DAO) were purchased from Nanjing Jiancheng Bioengineering Institute (Nanjing, China).
A total protein determination kit (BCA Protein Assay Kit) was acquired from Beyotime Institute
of Biotechnology (Haimen, China). Cytokines measurement kits were purchased from Lianke
Biotechnology CO., Ltd., (Hangzhou, China). RNAiso Plus Kit, Prime Script RT Reagent Kit, and SYBR
Premix Ex Taq TM (Tli RNaseH Plus) Kit were purchased from Takara Biotechnology (Dalian) Co.,
Ltd., (Dalian, China). Sulphuric acid, methanol, chloroform, acetic acid, diethyl ether, and petroleum
ether were purchased from the Sinopharm Chemical Reagent Co., Ltd., (Shanghai, China) and were of
an analytical grade. N-hexane was purchased from the Tianjin Shield Specialty Chemical Co., Ltd.,
(Tianjin, China) and was of an HPLC grade.
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2.2. Preparation of Hard-Shelled Mussel Lipid Extract (HMLE)
Hard-shelled mussels were collected from the Shengsi Islands in the Zhejiang province and HMLE
was prepared through the procedure of CO2 supercritical fluid extraction, which was previously
described [6]. Lipid composition of HMLE was also measured and reported in our previous study [7].
The lipid extract was then stored at −80 ◦C in amber vials to minimize autoxidation before use.
2.3. Animals and Experimental Design
Thirty-six 6-week-old male C57 mice were obtained from the Laboratory Animal Center of
Zhejiang University. They were maintained in an air-conditioned specific pathogen-free room with a
controlled temperature (22 ± 1 ◦C), constant humidity (55 ± 5%), and a normal 12-h light/dark cycle.
The animals were allowed ad libitum access to water and standard chows provided by the Laboratory
Animal Center during the experimental period. All experimental procedures were approved by the
Ethics Committee of the College of Biosystem Engineering & Food Science at Zhejiang University
(Reference: 2014005).
The experiment was performed as a 3 × 2 factorial design with the main factors being gavage
treatment and the LPS challenge. After one week of adaption, mice were randomly assigned to 3 groups
(n = 12 per group) including the solvent control group, the fish oil control group, and the HMLE group.
The solvent control group received olive oil by gavage at a volume of 5 mL/kg body weight daily [18].
Olive oil was commonly chosen as the solvent for mussel lipid extracts [6,19,20]. Fish oil and HMLE
groups received the same volume of olive oil containing fish oil and HMLE, respectively. The dose of
HMLE and fish oil was 300 mg/kg (around 6–8 mg/mouse). This dose was adapted from a previous
study where the New Zealand green-lipped mussel lipid extract (GMLE) was administrated to mice
with inflammatory bowel disease at a dose of 5 mg/mouse. It concluded that the optimal dose might
not have been achieved [20]. The fish oil group was selected as a positive control since it has already
been shown to enhance intestinal integrity in weaned pigs after the LPS challenge [21]. The fatty acid
profile of olive oil, fish oil, and HMLE used in this study is shown in Table 1. The calculated n-3 fatty
acid dose of three groups are 26.1 mg/kg (olive oil as linolenic acid), 208.7 mg/kg (fish oil, mainly EPA
and DHA), and 124.2 mg/kg (HMLE, mainly EPA and DHA).
During the treatment period, the body weight of mice was recorded at the same time of the
day every week. After 6 weeks, all mice underwent fasting for 12 h based on a previous study [21].
Then each treatment group was further randomly divided into two subgroups in which one received
the lipopolysaccharide (LPS) challenge and the other received sterile phosphate buffered saline (PBS).
The LPS-challenged groups were injected intraperitoneally with LPS at a dose of 10 mg/kg body
weight adapted from a previous study [22] while the unchallenged groups were injected with the
same amount of PBS. Four hours after injection, all mice were sacrificed under anesthesia using
diethyl ether. Blood samples were collected from the retro-orbital sinus to obtain erythrocytes. Ileac
and colonic segments were excised, freed of adherent adipose tissue, and then flushed with ice-cold
PBS. Afterward, ileac specimens were fixed in 10% formalin for morphology examination and colon
samples were cut into small pieces (n = 4 in total) for further experiments, which is described below.
The schematic of study design is shown in Figure 1.
2.4. Intestinal Morphology Examination
After a 24-h fixation in formalin, ileac segments were removed, dehydrated, and subsequently
embedded in paraffin. Then the segments were cut in 5–8 µm thick sections. These samples were
stained with hematoxylin and eosin and viewed under a light microscope (100×). The villus height and
the associated crypt depth were measured in accordance with previous studies [23,24]. Villus height is
defined as the distance from the villus tip to the crypt mouth and crypt depth is defined as the distance
from the crypt mouth to the base.
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2.5. Measurement of Erythrocyte Phospholipid Fatty Acids
Erythrocyte phospholipid fatty acids were measured using a standard method. The total lipids
of erythrocytes were extracted with chloroform/methanol (1:1) and the phospholipid fraction was
separated by using thin layer chromatography. Then the fatty acid methyl esters were prepared and
determined by using gas-liquid chromatography, which was previously described [25].
2.6. MPO and DAO Activity Assay, and Cytokines Measurement
For MPO activity measurements, colon samples were weighed and homogenized in 20 volumes
(w/v) of PBS containing 0.5% hexadecyltrimethylammonium. The homogenate was then centrifuged
at 1480 g for 15 min and the resulting supernatant was assayed for MPO activity using detection
kits. MPO activity was expressed in units per gram tissue. For DAO activity measurement, colon
samples were weighed and immersed into 10 volumes (w/v) of saline and then centrifuged at 1480 g
for 15 min. The supernatants were used to determine the total protein amount by utilizing the BCA
Protein Assay Kit as well as to determine DAO activity using the assay kit. DAO activity was calculated
and expressed in units per milligram protein. For colonic cytokines measurements, after centrifuging
the 10% (w/v) colon homogenates at 1480 g for 15 min, the supernatant was directly used to determine
cytokines including IL-1β, IL-6, IL-10, and TNF-αwith the help of detection kits. All measurements
were performed according to the manufacturers’ instructions.
2.7. Quantitative Real-Time Reverse Transcriptase-Polymerase Chain Reaction
Total RNA was isolated from colon samples using the RNAiso Plus Kit and cDNA was then
synthesized using the Prime Script RT Reagent Kit. Quantitative real-time PCR was performed in the
ABI ViiA 7 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) using the SYBR Premix
Ex Taq TM (Tli RNaseH Plus) Kit, according to the manufacturers’ instructions. The following forward
and reverse sequences were used: Occludin, forward 5′-GCTGTGATGTGTGTGAGCTG-3′ and reverse
5′-ATCTTTTGGGGTCCGTCAACT-3′; Claudin-1, forward 5′-TCAGGTCTGGCGACATTAGT-3′ and
reverse 5′-GACAGGAGCAGGAAAGTAGGA-3′; IL-1β, forward 5′-GCAACTGTTCCTGAACTCA
ACT-3′ and reverse 5′-ATCTTTTGGGGTCCGTCAACT-3′; IL-6, forward 5′-CTTCCATCCAGTTGC
CTTCTT-3′, and reverse 5′-AATTAAGCCTCCGACTTGTGAA-3′; IL-10, forward 5′-GCTCTTACTGA
CTGGCATGAG-3′ and reverse 5′-CGCAGCTCTAGGAGCATGTG-3′; TNF-α, forward 5′-CCCTCA
CACTCAGATCATCTTCT-3′, and reverse 5′-GCTACGACGTGGGCTACAG-3′; TLR-4, forward
5′-GGACTATGTGATGTGACCATTGAT-3′ and reverse 5′-TTATAGATACACCTGCCAGAGACA-3′;
MyD88, forward 5′-CTACAGAGCAAGGAATGTGACT-3′ and reverse 5′-ACCTGATGCCATTTGCTG
TCC-3′; IRAK4, forward 5′-ACATGCCCAACGGGTCCTT-3′ and reverse 5′-ACCTGATGCCATTTG
CTGTCC-3′; TRAF6, forward 5′-ATCACTTGGCACGACACTTG-3′ and reverse 5′-TAGGCGACTCTC
CAACTGTT-3′; and GAPDH, forward 5′-TGCTGAGTATGTCGTGGAGTC-3′ and reverse 5′-GGCGGA
GATGATGACCCTT-3′. The thermal cycling conditions were 30s at 95 ◦C, which was followed by
40 cycles of denaturation at 95 ◦C for 5 s and annealing at 60 ◦C for 34 s. A melting curve analysis
was performed at the end of the amplification cycles. The expression levels of target mRNA were
normalized to GAPDH as an internal control and the relative quantification of gene expressions was
performed using the 2−∆∆CT method [26]. Results were expressed as relative expression ratios to the
olive oil control group without the LPS challenge and the levels of gene expression in this group were
set to 1.0 [27].
2.8. Statistical Analysis
The data were expressed as a mean ± standard deviation (SD) and analyzed with SPSS 23.0
statistical software. Differences in body weight and erythrocyte phospholipid fatty acids among
three gavage treatments were tested using one-way ANOVA. This was followed by a Duncan’s
post-hoc test. For main outcomes including intestinal morphology, activity of DAO and MPO, colonic
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cytokines concentrations, and mRNA expression levels, two-way ANOVA was conducted to study
the interaction between gavage treatments and the LPS challenge. A significant interaction (p for
interaction < 0.05) indicated that the effects of gavage treatments were different between the LPS
challenged groups and the unchallenged groups. Interactions in which 0.05 < p < 0.10 were discussed
as trends. When there was a significant treatment effect (p for LPS challenge < 0.05 or p for gavage
treatment < 0.05). Afterward, a post-hoc test was conducted using one-way ANOVA followed by
Duncan’s test to compare the group difference. Except where otherwise specified, a two-sided p value
< 0.05 was considered significant. Superscripts were used to indicate the statistical differences and the
letter ‘a’ represents the highest value.
Table 1. Fatty acid composition of olive oil, fish oil, and HMLE.
Fatty Acid Olive Oil Fish Oil HMLE
C14:0 ND 4.37 ± 0.23 2.71 ± 0.09
C15:0 ND 0.27 ± 0.07 0.81 ± 0.06
C16:0 10.79 ± 0.46 8.84 ± 0.37 24.83 ± 0.87
C17:0 ND 0.98 ± 0.08 2.24 ± 0.09
C18:0 3.23 ± 0.16 1.43 ± 0.12 6.31 ± 0.13
C20:0 0.43 ± 0.08 0.12 ± 0.04 ND
Total SFA 14.06 ± 0.98 16.01 ± 1.07 36.90 ± 0.81
C16:1 0.82 ± 0.09 6.31 ± 0.43 7.28 ± 0.11
C17:1 ND 1.79 ± 0.16 3.10 ± 0.07
C18:1 77.27 ± 2.84 6.67 ± 0.54 4.55 ± 0.18
C20:1 ND 0.53 ± 0.03 5.81 ± 0.17
Total MUFA 78.08 ± 2.88 15.30 ± 1.13 20.72 ± 0.67
C18:2n-6 6.38 ± 0.11 0.99 ± 0.07 2.21 ± 0.09
C20:2n-6 ND 0.07 ± 0.02 0.52 ± 0.05
C20:3n-6 ND 0.16 ± 0.05 0.45 ± 0.04
C20:4n-6 ND 1.29 ± 0.34 2.83 ± 0.12
Total n-6 PUFA 6.38 ± 0.11 2.51 ± 0.37 6.01 ± 0.21
C18:3n-3 0.58 ± 0.08 1.01 ± 0.08 1.48 ± 0.06
C20:5n-3 ND 36.51 ± 3.27 13.06 ± 0.64
C22:5n-3 (EPA) ND ND 0.60 ± 0.05
C22:6n-3 (DHA) ND 23.93 ± 2.78 18.15 ± 0.97
Total n-3 PUFA 0.58 ± 0.08 61.45 ± 4.95 33.29 ± 0.96
ND, not detectable; SFA, saturated fatty acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty
acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid. Data are represented as the mean ± SD.
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The body weight of all the mice continued to increase with age during the six-week treatment
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polyunsaturated fatty acid compositions between olive oil control, and HMLE groups while none
of these fatty acids varied between olive oil control and fish oil control groups. However, n-3
polyunsaturated fatty acids including C18:3n-3, C20:5n-3 (EPA), C22:6n-3 (DHA), and total n-3increased
in both fish oil and HMLE groups when compared with the olive oil group.
Table 2. Effects of different gavage treatments on mice erythrocyte phospholipid fatty acid composition.
Olive Oil
(n = 12)
Fish Oil
(n = 12)
HMLE
(n = 12)
16:0 27.16 ± 1.35 27.41 ± 0.16 27.99 ± 4.69
18:0 10.25 ± 0.89 10.30 ± 0.72 9.07 ± 1.36
20:0 0.20 ± 0.03 0.20 ± 0.04 0.20 ± 0.06
22:0 0.58 ± 0.20 0.88 ± 0.26 0.77 ± 0.22
24:0 1.80 ± 0.38 2.01 ± 0.42 2.17 ± 0.37
Total SFA 39.99 ± 1.13 40.80 ± 0.98 40.19 ± 2.05
16:1 0.31 ± 0.05 0.39 ± 0.20 0.34 ± 0.20
18:1 14.85 ± 0.59 a 14.49 ± 0.52 ab 13.62 ± 0.97 b
20:1 0.35 ± 0.10 0.34 ± 0.12 0.30 ± 0.08
22:1 0.15 ± 0.04 0.15 ± 0.04 0.13 ± 0.07
24:1 0.77 ± 0.37 0.78 ± 0.06 0.88 ± 0.51
Total MUFA 16.43 ± 0.77 a 16.16 ± 0.46 ab 15.27 ± 0.97 b
18:2n-6 13.08 ± 0.63 13.27 ± 0.62 13.35 ± 1.00
18:3n-6 0.12 ± 0.05 0.09 ± 0.09 0.08 ± 0.04
20:2n-6 0.35 ± 0.02 0.32 ± 0.03 0.32 ± 0.03
20:3n-6 1.47 ± 0.08 1.41 ± 0.10 1.62 ± 0.22
20:4n-6 17.98 ± 1.46 16.34 ± 1.14 17.74 ± 4.42
22:2n-6 1.71 ± 0.24 1.65 ± 0.23 1.74 ± 0.35
Total n-6 PUFA 34.71 ± 1.53 33.07 ± 1.14 34.86 ± 1.27
18:3n-3 0.11 ± 0.06 b 0.25 ± 0.11 a 0.22 ± 0.08 a
20:5n-3 (EPA) 0.45 ± 0.08 b 0.59 ± 0.11 a 0.54 ± 0.07 a
22:6n-3 (DHA) 8.31 ± 0.32 b 9.21 ± 0.75 a 8.91 ± 0.41 a
Total n-3 PUFA 8.86 ± 0.47 b 10.04 ± 0.87 a 9.67 ± 0.59 a
SFA, saturated fatty acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; EPA,
eicosapentaenoic acid; DHA, docosahexaenoic acid. Data are represented as the mean ± SD. Values with different
letters in each row differ significantly according to one-way ANOVA and the Duncan post-hoc test (p < 0.05). The
letter ‘a’ represents the highest value.
3.2. Effects of HMLE on Intestinal Morphology and Activity of DAO and MPO
Morphology changes in the ileum of mice with LPS-induced intestinal injury are shown in Figure 3.
There was no interaction between gavage treatment and LPS observed for the villus height and crypt
depth in ileum (Table 3). Compared with mice receiving olive oil and fish oil, mice administered with
HMLE had a higher villus height in ileum (p for gavage treatment < 0.001). Mice challenged with
LPS had a lower villus height in ileum than those challenged with PBS (p for LPS challenge < 0.001).
Neither gavage treatment nor the LPS challenge had an effect on crypt depth.
Mice challenged with LPS had higher colonic MPO activity but lower DAO activity (both p for
LPS challenge < 0.001) (Table 3). Significant interaction between gavage treatment and LPS was
observed for both colonic MPO (p for interaction < 0.001) and DAO (p for interaction = 0.05) activity.
In comparison with olive oil, the administration of fish oil or HMLE lowered colonic MPO activity
and increased DAO activity among LPS-challenged mice while MPO and DAO activity did not differ
among PBS-treated mice. It is noteworthy that HMLE lowered MPO activity more than fish oil among
LPS-challenged mice.
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3.3. Effects of HMLE on Colonic Cytokines Secretion
Relative to mice injected with PBS, mice challenged with LPS had higher colonic cytokine
concentrations including IL-1β, IL-6, IL-10, and TNF-α (all p for LPS challenge < 0.001) (Table 4).
A trend for interaction between gavage treatment and LPS was observed for colonic IL-1β (p for
interaction = 0.06) and IL-6 (p for interaction = 0.06) secretion in which mice administered with
fish oil or HMLE had lower colonic IL-1β and IL-6 concentrations among LPS-treated mice while
IL-1β and IL-6 did not vary among PBS-treated mice. There was a significant interaction between
gavage treatment and LPS observed for colonic IL-10 (p for interaction < 0.001) and TNF-α (p for
interaction = 0.04) concentration (Table 4). Similarly, IL-10 and TNF-α concentration did not differ
among PBS-treated mice, but mice treated with fish oil or HMLE had a higher concentration of IL-10
and a lower concentration of TNF-α than those treated with olive oil among the LPS-challenged mice.
3.4. Effects of HMLE on Colonic mRNA Expression
For colonic mRNA expression levels of tight junction proteins, there was no interaction between
gavage treatment and LPS observed for occludin and claudin-1 (Table 5). Treatment with fish oil or
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HMLE increased mRNA expression levels of these two tight junction proteins (both p for gavage
treatment < 0.001) relative to the olive oil. Mice challenged with LPS had lower mRNA expression
levels of occuldin and claudin-1 (both p for LPS challenge < 0.001) in comparison with those treated
with PBS.
Compared with PBS-treated mice, LPS-challenged mice had higher mRNA expression of
IL-1β, IL-6, IL-10, and TNF-α (all p for LPS challenge < 0.001) (Table 5). Significant interactions
between gavage treatment and LPS was observed for colonic mRNA expression of cytokines IL-1β
(p for interaction = 0.001), IL-6 (p for interaction = 0.002), IL-10 (p for interaction < 0.001), and TNF-α
(p for interaction < 0.001). Treatment with fish oil or HMLE was associated with reduced mRNA
expression levels of IL-1β, IL-6, and TNF-α and increased levels of IL-10. These effects were larger
among LPS-challenged mice than among PBS-treated mice. Notably, the lowering effect of fish oil on
the mRNA level of TNF-αwas better than that of HMLE among LPS-challenged mice.
Among four key molecules in the TLR-4 signaling pathway, mice challenged with LPS had
a higher mRNA abundance of colonic TLR-4 (p for LPS challenge < 0.001) and MyD88 (p for LPS
challenge < 0.001) compared with mice injected with PBS (Table 5). There was a significant interaction
between gavage treatment and LPS observed for TLR-4 (p for interaction < 0.001). A trend for
interaction between gavage treatment and LPS was found for MyD88 (p for interaction = 0.07) so that
the responses of these variables were lower in mice receiving fish oil or HMLE when compared with
those receiving olive oil. These effects were larger among LPS-challenged mice compared with those
in the PBS-treated mice. No interaction between gavage treatment and LPS was observed for mRNA
expressions of IRAK4 and TRAF6. Neither gavage treatment nor the LPS challenge had an effect on
these two genes.
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Table 3. Effects of different gavage treatments on ileac villus height and crypt depth and colonic DAO and MPO activity.
PBS LPS p Value
Olive Oil
(n = 6)
Fish Oil
(n = 6)
HMLE
(n = 6)
Olive Oil
(n = 6)
Fish Oil
(n = 6)
HMLE
(n = 6)
Gavage
Treatment LPS Challenge Interaction
Ileac villus height (µm) 256.4 ± 15.3 b 255.3 ± 18.5 b 281.4 ± 19.7 a 212.3 ± 22.8 c 222.9 ± 11.9 c 259.2 ± 15.0 ab <0.001 <0.001 0.40
Ileac crypt depth (µm) 76.9 ± 17.14 76.9 ± 11.9 80.8 ± 20.2 87.3 ± 14.4 85.6 ± 10.2 85.7 ± 16.9 0.94 0.10 0.89
Colonic DAO activity (U/mg protein) 0.21 ± 0.05 a 0.21 ± 0.03 a 0.20 ± 0.03 a 0.08 ± 0.03 c 0.12 ± 0.02 b 0.13 ± 0.02 b 0.36 <0.001 0.05
Colonic MPO activity (U/g tissue) 0.58 ± 0.08 d 0.63 ± 0.09 d 0.57 ± 0.08 d 1.98 ± 0.25 a 1.52 ± 0.09 b 1.30 ± 0.06 c <0.001 <0.001 <0.001
Data are represented as the mean ± SD. Values with different letters in each row differ significantly according to one-way ANOVA and the Duncan post-hoc test (p < 0.05). The letter ‘a’
represents the highest value.
Table 4. Effects of different gavage treatments on colonic cytokines secretion.
PBS LPS p Value
Olive Oil
(n = 6)
Fish Oil
(n = 6)
HMLE
(n = 6)
Olive Oil
(n = 6)
Fish Oil
(n = 6)
HMLE
(n = 6)
Gavage
Treatment LPS Challenge Interaction
Colonic IL-1β (pg/g tissue) 607.2 ± 70.4 c 589.2 ± 35.5 c 590.9 ± 55.6 c 1034.5 ± 89.1 a 814.9 ± 147.7 b 749.1 ± 96.5 bc 0.03 <0.001 0.06
Colonic IL-6 (pg/g tissue) 378.1 ± 76.3 c 409.2 ± 100.8 c 365.0 ± 76.8 c 932.0 ± 90.4 a 745.7 ± 83.3 b 675.4 ± 88.1 b 0.06 <0.001 0.06
Colonic IL-10 (ng/g tissue) 15.5 ± 2.0 c 14.0 ± 1.8 c 13.1 ± 2.5 c 22.4 ± 1.2 b 29.4 ± 2.6 a 32.4 ± 1.6 a 0.02 <0.001 <0.001
Colonic TNF-α (pg/g tissue) 418.8 ± 77.9 c 403.4 ± 26.6 c 435.9 ± 64.2 c 985.8 ± 46.5 a 848.5 ± 42.6 b 832.9 ± 44.7 b 0.05 <0.001 0.04
Data are represented as the mean ± SD. Values with different letters in each row differ significantly according to one-way ANOVA and the Duncan post-hoc test (p < 0.05). The letter ‘a’
represents the highest value.
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Table 5. Effects of different gavage treatments on colonic mRNA expression.
PBS LPS p Value
Olive Oil
(n = 6)
Fish Oil
(n = 6)
HMLE
(n = 6)
Olive Oil
(n = 6)
Fish Oil
(n = 6)
HMLE
(n = 6)
Gavage
Treatment LPS Challenge Interaction
Colonic tight junction
proteins
occludin 1.00 b 1.14 ± 0.07 a 1.14 ± 0.08 a 0.63 ± 0.04 c 0.77 ± 0.07 b 0.82 ± 0.04 b <0.001 <0.001 0.56
claudin-1 1.00 bc 1.06 ± 0.07 a 1.11 ± 0.08 ab 0.80 ± 0.03 d 0.95 ± 0.07 c 0.98 ± 0.09 c <0.001 <0.001 0.21
Colonic cytokines
IL-1β 1.00 c 0.77 ± 0.04 d 0.85 ± 0.04 d 1.71 ± 0.18 a 1.15 ± 0.06 b 1.12 ± 0.32 bc <0.001 <0.001 0.001
IL-6 1.00 c 0.94 ± 0.03 c 0.94 ± 0.02 c 2.73 ± 0.21 a 1.90 ± 0.10 b 1.87 ± 0.31 b 0.001 <0.001 0.002
IL-10 1.00 c 1.05 ± 0.03 c 1.02 ± 0.04 c 1.47 ± 0.21 b 2.60 ± 0.10 a 2.60 ± 0.20 a <0.001 <0.001 <0.001
TNF-α 1.00 d 0.70 ± 0.05 d 0.79 ± 0.03 d 7.71 ± 0.54 a 2.43 ± 0.23 c 4.34 ± 0.37 b <0.001 <0.001 <0.001
Key molecules in the
TLR-4 signaling pathway
TLR-4 1.00 c 0.91 ± 0.04 d 0.91 ± 0.03 d 1.76 ± 0.07 a 1.22 ± 0.04 b 1.23 ± 0.02 b <0.001 <0.001 <0.001
MyD88 1.00 c 0.97 ± 0.02 c 0.94 ± 0.03 c 3.86 ± 0.37 a 3.14 ± 0.36 b 3.16 ± 0.38 b 0.04 <0.001 0.07
IRAK4 1.00 0.98 ± 0.05 0.97 ± 0.06 1.14 ± 0.19 1.01 ± 0.05 1.04 ± 0.05 0.29 0.14 0.40
TRAF6 1.00 0.97 ± 0.06 0.96 ± 0.07 1.07 ± 0.09 1.04 ± 0.09 0.99 ± 0.05 0.30 0.10 0.82
Data are represented as the mean ± SD. Values with different letters in each row differ significantly according to one-way ANOVA and the Duncan post-hoc test (p < 0.05). The letter ‘a’
represents the highest value.
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4. Discussion
It is possible that, due to the high content of n-3 PUFA such as EPA and DHA, HMLE has been
shown to exert beneficial effects on arthritis and ulcerative colitis in animal models and in clinical
trials [6,13–15]. On the basis of this, we examined the potential protective effect of HMLE on intestinal
morphology and barrier function after an injury was induced by LPS with the use of a mouse model
(Figure 4). In our study, an erythrocyte phospholipid fatty acid profile analysis demonstrated that,
like fish oil, administration of HMLE could result in the enrichment of EPA, DHA, and total n-3 PUFA
in the mice.
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This was subs antiated by our results th t colonic MPO activity, whi h is an indic tor of the degree of
neutrophil infiltration [29], was increased af er the LPS challenge. However, the level of colonic MPO
activity was dramatically de reased in both fish oil an HMLE groups among LPS-challenged mice,
which suggests colonic MPO activity has an anti-i flammatory effect. Similarly, the effect f HMLE
was significantly be ter than the effect of fish oil with lower MPO activity.
DAO is an enzyme deaminating histamine and polyamines and its highest activity is found in the
intestinal mucosa in most m m lian species [30]. The activity of DAO in intestinal mucosa decreases
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when these cells are injured [31]. Therefore, it is a relatively stable marker of intestinal mucosa integrity
and barrier function. Our study demonstrated that, compared with olive oil, both fish oil and HMLE
increased DAO activity. These results indicate that, like fish oil, HMLE could alleviate the injury
of the intestinal barrier function induced by an LPS injection. As for the intestinal barrier function,
tight junctions between epithelial cells are the major components [32]. It has been reported that tight
junctions are composed of 40 different proteins in which occludin and claudins are thought of as the
major integral membrane proteins [33]. Fish oil has been shown to be able to prevent an LPS-induced
decrease in occludin and claudin-1 expression in pig models [21]. In the current study, HMLE also
tended to enhance the colonic mRNA expression level of occludin and claudin-1 independent of the
LPS challenge. HMLE may partially improve the intestinal barrier function by enhancing the mRNA
expression of intestinal tight junction proteins.
It is increasingly recognized that cytokines also participate in regulating the intestinal tight
junction barrier. Pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α could cause an increase
in the permeability of tight junctions [34]. Such effects appear to be an essential mechanism leading to
intestinal inflammation. In our study, the LPS challenge significantly increased colonic IL-1β, IL-6,
and TNF-α levels while fish oil and HMLE treatments were associated with preventing such increases
among LPS-challenged mice. IL-10 is considered an important anti-inflammatory cytokine secreted by
T-cells and it seems to be protective against the tight junction barrier disturbance [35]. Our data showed
that the colonic IL-10 level was increased after the LPS challenge. This might be due to the nature of
the acute study design. It is possible that IL-10 concentration might increase due to the inflammation
caused by LPS in the early period, but will decrease in the long run, which was observed in a mouse
model where colonic IL-10 concentration was decreased after chronic inflammation [15]. Nevertheless,
in the present study, the colonic level of IL-10 was further increased in mice receiving fish oil and
HMLE compared with those receiving olive oil. Consistent with attenuated pro-inflammatory cytokine
levels and an improved anti-inflammatory cytokine level by fish oil and HMLE administration, fish oil
and HMLE decreased the IL-1β, IL-6, and TNF-α gene expression and increased IL-10 relative to olive
oil, which suggests that this might be one of the mechanisms of how HMLE prevents the deleterious
effects of intestinal injury induced by the LPS challenge in mice.
The transmembrane TLRs are a family of pattern-recognition receptors that play a critical role
in recognizing microbial pathogens and modulating the innate immune systems [36]. Among this
family, TLR-4 is the most-extensively-studied member. When activated by endotoxin or LPS from
Gram-negative bacteria, TLR-4 recruits adaptor proteins such as MyD88 and delivers a signal, which is
passed forward by a series of IRAK and TRAF6. This process activates NF-κB, which transduces the
signal to the nucleus and results in activation of the inflammatory genes such as pro-inflammatory
cytokines [37]. TLR-4 has been reported to be expressed at low levels in basal conditions in vivo but it
is upregulated in inflammatory bowel disease [38]. In addition, the effect of LPS was largely inhibited
after TLR-4 or MyD88 knockdown and completely blunted in TLR-4 knockout mice [39]. Therefore, the
TLR-4 signaling pathway may play a critical role in intestinal inflammation and defense. In the present
study, treatment with fish oil and HMLE significantly inhibited the increased expression of TLR-4
and MyD88 in the colon tissue of LPS-challenged mice. Considering the decreased mRNA expression
of pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α, it is possible that the protective
effects of HMLE administration on the intestinal barrier function were closely related to reducing the
expression of intestinal pro-inflammatory cytokines by inhibiting the TLR-4 signaling pathway.
In our study, administration of HMLE significantly improved erythrocyte n-3 PUFA levels
in mice and HMLE exhibited comparable or, in some instances, even better protective effects
than fish oil on intestinal barrier function during an LPS-induced injury such as restoration of
the ileac villus height and inhibition of increased colonic MPO activity. Therefore, similar to fish
oil, the n-3 PUFAs in HMLE might be responsible for the protective effects. Some researchers
have studied the active components in another marine mussel lipid extract reported to have
anti-inflammatory effects—GMLE. They identified some novel anti-inflammatory n-3 PUFAs such as
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5,9,12,15-octadecatetraenoic acid, 5,9,12,16-nonadecatetraenoic acid, 7,11,14,17-eicosatetraenoic acid,
and 5,9,12,15,18-heneicosapentaenoic acid other than EPA and DHA [40]. However, the protective
effects of HMLE could not be solely ascribed to n-3 PUFAs since HMLE was more effective in the
previously mentioned aspects than in fish oil. However, the n-3 PUFAs content in HMLE is lower
than in the fish oil (124.2 mg/kg vs. 208.7 mg/kg). Likewise, a previous study indicated that GMLE
also contained much lower content of n-3 PUFA than that of tuna oil but exhibited much higher
anti-inflammatory activity than tuna oil [41]. One study on GMLE reported novel active compounds
called furan fatty acids, which do not belong to n-3 PUFAs, but had a higher anti-inflammatory activity
than EPA [42,43]. As for HMLE, further studies would be needed to identify new potential active
compounds and investigate whether the protective effects could be attributed to any single lipid class,
a single fatty acid, or the summative effect of different lipid classes and combinations of different
fatty acids.
5. Conclusions
In summary, like fish oil, HMLE exerts beneficial effects in improving intestinal integrity after
the LPS challenge in mice. It is possible that this protective effect on the intestine might be due in
part to regulation of the production and expression of both pro-inflammatory and anti-inflammatory
cytokines as well as the downregulation of the TLR-4 signaling pathways.
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